Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of high-dose ambroxol in newly diagnosed or prodromal GBA1-associated Parkinson's disease
MOH_2023-06-18_012746Phase 2Not yet recruiting
- Sponsor
- Agyany Pharma
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ambroxol in Parkinson's disease (PD) (2 arms), sponsored by Agyany Pharma. Primary endpoint: Safety of high-dose ambroxol. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
ambroxol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2023-06-18_012746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-18_012746.